These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25238700)

  • 1. Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review.
    Surcel CI; van Oort IM; Sooriakumaran P; Briganti A; De Visschere PJ; Fütterer JJ; Ghadjar P; Isbarn H; Ost P; van den Bergh RC; Yossepowitch O; Giannarini G; Ploussard G;
    Urol Oncol; 2015 Jun; 33(6):265.e1-7. PubMed ID: 25238700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.
    Conteduca V; Aieta M; Amadori D; De Giorgi U
    Crit Rev Oncol Hematol; 2014 Oct; 92(1):11-24. PubMed ID: 24952997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine differentiation in the progression of prostate cancer.
    Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
    Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretogranin II is overexpressed in advanced prostate cancer and promotes the neuroendocrine differentiation of prostate cancer cells.
    Courel M; El Yamani FZ; Alexandre D; El Fatemi H; Delestre C; Montero-Hadjadje M; Tazi F; Amarti A; Magoul R; Chartrel N; Anouar Y
    Eur J Cancer; 2014 Nov; 50(17):3039-49. PubMed ID: 25307750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma.
    Sagnak L; Topaloglu H; Ozok U; Ersoy H
    Clin Genitourin Cancer; 2011 Dec; 9(2):73-80. PubMed ID: 22035833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.
    Tawadros T; Alonso F; Jichlinski P; Clarke N; Calandra T; Haefliger JA; Roger T
    Endocr Relat Cancer; 2013 Feb; 20(1):137-49. PubMed ID: 23207293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
    Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.
    Hirano D; Okada Y; Minei S; Takimoto Y; Nemoto N
    Eur Urol; 2004 May; 45(5):586-92; discussion 592. PubMed ID: 15082200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling.
    Lin TP; Chang YT; Lee SY; Campbell M; Wang TC; Shen SH; Chung HJ; Chang YH; Chiu AW; Pan CC; Lin CH; Chu CY; Kung HJ; Cheng CY; Chang PC
    Oncotarget; 2016 May; 7(18):26137-51. PubMed ID: 27034167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.
    Marchiani S; Tamburrino L; Nesi G; Paglierani M; Gelmini S; Orlando C; Maggi M; Forti G; Baldi E
    Int J Androl; 2010 Dec; 33(6):784-93. PubMed ID: 20088946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells.
    Humez S; Monet M; Legrand G; Lepage G; Delcourt P; Prevarskaya N
    Endocr Relat Cancer; 2006 Mar; 13(1):181-95. PubMed ID: 16601287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.
    Abrahamsson PA; Cockett AT; di Sant'Agnese PA
    Prostate Suppl; 1998; 8():37-42. PubMed ID: 9690662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance.
    Marcu M; Radu E; Sajin M
    Rom J Morphol Embryol; 2010; 51(1):7-12. PubMed ID: 20191113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of TGF-β - SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK.
    Natani S; Sruthi KK; Asha SM; Khilar P; Lakshmi PSV; Ummanni R
    Cell Signal; 2022 Mar; 91():110240. PubMed ID: 34986386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.
    Blanc C; Moktefi A; Jolly A; de la Grange P; Gay D; Nicolaiew N; Semprez F; Maillé P; Soyeux P; Firlej V; Vacherot F; Destouches D; Amiche M; Terry S; de la Taille A; Londoño-Vallejo A; Allory Y; Delbé J; Hamma-Kourbali Y
    Br J Cancer; 2023 Mar; 128(5):918-927. PubMed ID: 36550208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of neuroendocrine cells in prostate cancer: a comprehensive review of current literature and subsequent rationale to broaden and integrate current treatment modalities.
    Lugnani F; Simone G; Biava PM; Ablin RJ
    Curr Med Chem; 2014; 21(9):1082-92. PubMed ID: 24304274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of neuroendocrine components in gastric carcinomas.
    Park JY; Ryu MH; Park YS; Park HJ; Ryoo BY; Kim MG; Yook JH; Kim BS; Kang YK
    Eur J Cancer; 2014 Nov; 50(16):2802-9. PubMed ID: 25201164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.